Aurinia: LUPKYNIS® (voclosporin) Effective in Treatment Targets in Lupus

 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, presented data demonstrating the efficacy of LUPKYNIS® (voclosporin) for the treatment of people with lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE), in achieving the proteinuria treatment targets recommended by the European Alliance of Associations for Rheumatology (EULAR) and the European Renal Association (ERA). A post-hoc analysis of pooled data from the similarly designed 48-week AURA-LV and 52-week AURORA 1 studies were presented in an oral session at the EULAR 2022 European Congress of Rheumatology by Hans-Joachim Anders, M.D., Professor of Nephrology at the University of Munich (LMU).

The pooled analysis from the Phase 2 AURA-LV and Phase 3 AURORA 1 studies assessed the efficacy of voclosporin, in addition to mycophenolate mofetil (MMF) and low-dose steroids, to reduce urine protein creatinine ratio (UPCR) to achieve the following EULAR/ERA treatment targets updated in 2019: ≥25% reduction in UPCR by three months, ≥50% reduction in UPCR by six months, UPCR ≤0.7 mg/mg by 12 months, as well as steroid dose of ≤7.5 mg/day at 12 months.

https://finance.yahoo.com/news/aurinia-presents-data-demonstrating-lupkynis-110500197.html